- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06658093
RESTOR: PK/PD mTORi Inhibition in Older Adults (RESTOR)
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be done in three parts, each with different human subject groups. Participants may only enroll in one of the sub-studies.
Sub-study 1: Determining target mTOR activity values in YOUNG untreated subjects (ages 20-30 years): NOTE: This aim of the study is not a clinical trial, so this population will not be included in participant flow or included as an arm in the study.
This study defines "best dose" as the choice of drug, dose, and frequency that will come closest to restoring the "youthful" levels of mTOR activity in an older individual. The investigators first need to measure mTOR activity in young untreated subjects to define these target "youthful" mTOR activity levels.
Sub-study 2. Finding the most effective drug, dose, and timing for dosing for oral dosing of the mTOR inhibitor drugs in older adults (65-90 years):
Healthy older persons will be recruited for a short-term (6 week treatment plus 4 week follow-up) dose-finding study. The most effective, but safe dose will then be tested in a larger number of subjects in Sub-study 3. Importantly, the best drug and dose regimen for females may differ from the one determined for males so the cohort will include both sexes.
Sub-study 3. Placebo controlled trial testing of DAILY (sustained) vs. INTERMITTENT mTOR inhibition in older human males and females:
Sub-study 3 will enroll healthy older persons (65-90 yrs) for a long-term clinical trial (6 months of treatment plus 6 months of follow-up) with 3 test groups:
i) best DAILY dose/drug; ii) best INTERMITTENT dose/drug/interval, and iii) PLACEBO (a pill that looks identical to the medicine, but has no drug in it).
This study will help find out what effects, good and/or bad, Rapamycin or Everolimus have on older people who take the drug for a longer period of time. The safety of Rapamycin and Everolimus in humans has been tested in prior research studies; however, some side effects may not yet be known in healthy older persons. By completing the entire study, the Research Team hopes to learn more about how older human subjects can best be treated using these drugs (mTOR inhibitors) to help them live longer, healthier lives.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Ellen Kraig, PhD
- Phone Number: (210) 367-3171
- Email: kraig@uthscsa.edu
Study Contact Backup
- Name: Dean L Kellogg, Jr, MD PhD
- Phone Number: (210) 617 5197
- Email: kelloggd@uthscsa.edu
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- The University of Texas Health Science Center at San Antonio
-
Contact:
- Dean L Kellogg Jr.,, MD PhD
- Phone Number: 210-617-5197
- Email: kelloggd@uthscsa.edu
-
Principal Investigator:
- Dean L Kellogg Jr., MD PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):
- Age ≥65 to 90 years
- Men and women
- In good health with all medical problems stable.
- Community-dwelling
- Agreement to adhere to Lifestyle Considerations throughout study duration.
- Ability of participant to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):
- Resident of nursing home or long-term care facility
- Subjects with diabetes or currently taking glucose lowering medications
- History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation); Moderate to severe valvular heart disease
- Active cancer or history of cancer treatment within the last 5 years
- Chronic inflammatory condition, autoimmune disease, or infectious processes (e.g., active tuberculosis, HIV, rheumatoid arthritis, systemic lupus erythematosus, acute or chronic hepatitis B or C)
- History of a coagulopathy or any medical condition requiring anticoagulation (except low dose ASA)
- Renal insufficiency with an estimated glomerular filtration rate of <30ml/min
- Uncontrolled hypercholesterolemia >350mg/dl or uncontrolled hypertriglyceridemia >500mg/dl
- Anemia or abnormal blood cell counts: hemoglobin level <9.0g.dl; white blood count <3500/mm3; neutrophil count <2000/ mm3; platelet count <125,000/mm3
- History of skin ulcers or poor wound healing
- Active tobacco use (within 6 months)
- Diagnosis of any disabling neurologic disease such as Parkinson's Disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual deficits (muscle weakness or gait disorder), severe neuropathy, diagnosis of dementia or Clox1 score less than 10 at the time of screening visit, cognitive impairment due to any reason such that the patient is unable to provide informed consent
- Liver disease
- Systemic treatment with an immunosuppressant (prednisone, etc.) within the year prior to enrollment
- Treatment with drugs known to affect cytochrome P450 (CYP3A4), i.e., diltiazem, erythromycin.
- Patients with history of recent (within 6 months) myocardial infarction or active coronary disease
- Patients with history of recent (within 6 months) intestinal disorders
- History of severe head trauma, brain injury, brain surgery, inflammation of the brain, or history of seizure disorder
- History of Long-Covid (PASC) within one year
- Acute Covid19 or Covid19 infection within the last 6 months
- Unwilling to forgo grapefruit juice consumption.
- Participation in mTORi study within the prior year. (Note: participants in AIM 1 will be excluded from participating in AIM 2 of the proposed trial.)
- Allergic to RAPA or EVERO
- Allergic to lidocaine
- Recreational drug use
- Donated blood over a two-month period prior to study initiation.
- Currently using cannabidiol (CBD) or tetrahydrocannabinol (THC) or any preparation contained these, or related, substances.
- Currently using hormone replacement or modulating therapies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin
Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men. In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design. |
mTOR inhibitor
Other Names:
|
|
Experimental: Aim 1: Sub-study 2 Daily dosing Cohort Everolimus
Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men. In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) of everolimus (EVERO) in milligrams based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design. |
mTOR inhibitor
Other Names:
|
|
Experimental: Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin
Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men. In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design. |
mTOR inhibitor
Other Names:
|
|
Experimental: Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus
Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men. In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of everolimus (EVERO) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design. |
mTOR inhibitor
Other Names:
|
|
Experimental: Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor
Based on the findings from Aim 1, the optimal drug (RAPA or EVERO) and dose for DAILY delivery will be tested in a blinded placebo-controlled trial in older human subjects.
The drug/dose used in males may differ from the one used in females as the OD will be determined independently for the two sexes.
PD parameters 'downstream' from mTOR will be followed.
|
mTOR inhibitor
Other Names:
mTOR inhibitor
Other Names:
|
|
Experimental: Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor
Based on the findings from Aim 1, the optimal drug (RAPA or EVERO), interval between doses, and dose for INTERMITTENT delivery will be tested in a blinded placebo-controlled trial in older human subjects.
The drug/dose/interval used in males may differ from the one used in females as the OD will be determined independently for the two sexes.
PD parameters 'downstream' from mTOR will be followed.
Although drug is delivered on an intermittent schedule, subjects will be given a pill each day (either drug or placebo, as scheduled) to maintain blinding.
|
mTOR inhibitor
Other Names:
mTOR inhibitor
Other Names:
|
|
Placebo Comparator: Aim 2: Sub-study 3 Placebo control
Daily administration of a placebo will be given to a cohort of older human subjects.
Both males and females will be enrolled as controls.
|
Inert placebo for rapamycin or everolimus
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)
Time Frame: Baseline to study end (approximately 12 months)
|
The level of soluble (s)ICAM-1 will be measured in serum.
|
Baseline to study end (approximately 12 months)
|
|
Pharmacokinetics (PK) of mTOR inhibitor in blood
Time Frame: Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)
|
The levels of the study drug will be measured in whole blood
|
Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)
|
|
PD measure of inhibition of mTOR activity in blood cells - p-rpS6
Time Frame: Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)
|
Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.
|
Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PD measure of inhibition of mTOR activity in PBMCs Akt
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from PBMCs will be analyzed for phosphorylation of Akt, downstream of mTORC2.
|
Baseline to study end (approximately 12 months)
|
|
PK of mTOR inhibitor in fat (Aim 2 only)
Time Frame: Baseline and study end (approximately 12 months)
|
The levels of the study drug will be measure in fat tissue obtained by adipose biopsy
|
Baseline and study end (approximately 12 months)
|
|
PK of mTOR inhibitor in muscle (Aim 2 only)
Time Frame: Baseline to study end (approximately 12 months)
|
The levels of the study drug will be measured in skeletal muscle obtained by biopsy.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in fat cells (Aim 2 only) - pS6K
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from adipose tissue will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in muscle (Aim 2 only) - pS6K
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from skeletal muscle tissue biopsy will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in adipose cells, rpS6 (Aim 2 only)
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from adipose biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in muscle rpS6 (Aim 2 only)
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from muscle biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in adipose (fat) cells Akt (Aim 2 only)
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from adipose biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in muscle Akt (Aim 2 only)
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from muscle biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.
|
Baseline to study end (approximately 12 months)
|
|
PD measure of inhibition of mTOR activity in PBMCs, S6-kinase
Time Frame: Baseline to study end (approximately 12 months)
|
Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.
|
Baseline to study end (approximately 12 months)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ellen Kraig, PhD, The University of Texas Health Science Center at San Antonio
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000471
- U01AG089242 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.